MMH-MAP

DRUG2 trials

Sponsors

Materia Medica Holding

Conditions

Cognitive DisordersIschemic StrokeMild Cognitive Impairment

Phase 3

Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke

CompletedNCT03815292

Materia Medica HoldingIschemic Stroke, Mild Cognitive Impairment

Start: 2018-10-19End: 2020-01-27Updated: 2021-02-23

Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders

CompletedNCT04295681

Materia Medica HoldingCognitive Disorders

Start: 2019-12-12End: 2023-02-07Updated: 2024-10-28